MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock through...
$17,155K
Proceeds from issuance of
common shares upon...
$714K
Net cash provided by
financing activities
$11,469K
Canceled cashflow
$6,400K
Net increase
(decrease) in cash and cash...
-$165,461K
Canceled cashflow
$11,469K
Maturities of marketable
securities
$60,250K
Stock-based compensation
expense
$11,691K
Accounts payable
$788K
(gain) loss from
changes in fair value of...
$214K
Depreciation expense
$213K
Non-cash interest
expense
$163K
Non-cash lease expense
$125K
Other assets
-$24K
Loss on disposal of
property and equipment
-$23K
Term loan principal
payments
$6,000K
Deferred offering costs
paid
$336K
Issuance costs paid on
at-the market offering
$64K
Net cash used in
investing activities
-$95,216K
Net cash used in
operating activities
-$81,627K
Canceled cashflow
$60,250K
Canceled cashflow
$13,241K
Effect of changes in
exchange rate on cash and...
-$87K
Purchases of marketable
securities
$154,747K
Net loss
-$80,605K
Deferred revenue
-$6,746K
Purchase of property and
equipment
$719K
Accrued expenses and
other current...
-$3,412K
Prepaid expenses and
other current assets
$1,713K
Accretion of net
investment discounts
$1,623K
Accounts receivable
$769K
Back
Back
Cash Flow
source: myfinsight.com
BioAge Labs, Inc. (BIOA)
BioAge Labs, Inc. (BIOA)